Ann: Immutep Corporate Presentation, page-128

Hi Joe. That is a difficult question to answer. I also chatted with my Oncology Clinica Trial Coordinator friend and she could not give a definative answer either but what we know is that the answer varies with the disease. With aggressive cancers a good ORR or DCR is sometimes very low, and perhaps 30% ORR is generally getting into a good (or at least encouraging) outcome zone (in absence of an adverse side effect) specially at this earlt stage of immunotherapy. Personslly (i.e., AIMO) i am happy with 40-50% ORR and 80%+ DCR for AIPAC IIb so far for example.

Also have a look at the cluster analysis diagram in this link below. It is not a general diagram and specific to some studies but is an interesting concept ... It may be hard to get the head around it. So, here is a little explanation: the capital letters are different arms (on different drug combos). The diagram looks at the relationship between 4 different parametres: 1 yr PFS, 1 yr OS, DCR and ORR. Now, take any two parametres and find the square (cluster plot) where they intersec. Then the axis represent % of each parameter respectively. For example, top right square is the cluster analisis between 1yr PFS and ORR (likewise the bottom left square - with axis swapped).

https://images.app.goo.gl/5UZhVc7EUUngAh8GA

And IMO if we ger evern 10% advantage in ORR over the control group (e.g. with Paclitaxel alone) then i would say we are onto something ... but i would mot want to do the crystal ball analysis here.